Clinical Trials Logo

Hepatitis, Chronic clinical trials

View clinical trials related to Hepatitis, Chronic.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05760781 Terminated - Chronic Hepatitis b Clinical Trials

To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Start date: April 25, 2023
Phase: Phase 2
Study type: Interventional

This trial is a multi-center, open, single-dose, dose-increasing trial,to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy.

NCT ID: NCT05760703 Terminated - Chronic Hepatitis b Clinical Trials

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Start date: April 25, 2023
Phase: Phase 2
Study type: Interventional

This trial is a multi-center, open, single-dose, dose-increasing trial,to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).

NCT ID: NCT05674448 Terminated - Clinical trials for Chronic Hepatitis B and Hepatitis D Co-infection

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label phase IIa study of HH-003 to evaluate its antiviral activity and safety in subjects with chronic hepatitis B and hepatitis D co-infection. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.

NCT ID: NCT05561530 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Start date: October 7, 2022
Phase: Phase 1
Study type: Interventional

A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects

NCT ID: NCT05238844 Terminated - Chronic Hepatitis b Clinical Trials

A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection

Start date: April 11, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in volunteers with chronic hepatitis B virus infection. Volunteers will be administered multiple oral doses of ATI-2173 vebicorvir in combination with tenofovir disoproxil fumarate and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.

NCT ID: NCT05001022 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Start date: September 25, 2021
Phase: Phase 1
Study type: Interventional

A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

NCT ID: NCT04971512 Terminated - Clinical trials for Chronic Hepatitis B Virus Infection

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Start date: August 2, 2021
Phase: Phase 1
Study type: Interventional

Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in healthy subjects. Part 2 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of EDP-721 in combination with EDP-514 in patients with chronic hepatitis B virus infection.

NCT ID: NCT04820686 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

NCT ID: NCT04781647 Terminated - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha (Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)

NCT ID: NCT04775797 Terminated - Chronic Hepatitis Clinical Trials

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

Start date: June 25, 2021
Phase: Phase 1
Study type: Interventional

This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2a/b will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.